.png){kind=logo}
.webp)
PREDICTIVE MODELS CREATION▪ IMMUNOPROFILING ▪️ MODE OF ACTION ▪️ TRANSLATIONAL PRECLINICAL SERVICES ▪️ TARGET VALIDATION ▪️ TARGET OPTIMIZATION ▪️ TUMOR MICRO-ENVIRONMENT ▪️ GENE ENGINEERING ▪️ CRISPR-CAS9
.png)
Drug discovery and development is a long, complex, costly, and high-risk process that takes over 10–15 years with an average cost of over $1–2 billion for each new drug to be approved for clinical use.
Advance a therapeutic candidate to phase I clinical trial is very challenging.
JC Discovery® has developped the Fast-TrackTM Solutions to help you take the decisions at the discovery stage and give your drug candidate the best chance to enter and succeed in the preclinical and clinical phases.
Source: Why 90% of clinical drug development fails and how to improve it?
Duxin Sun, Wei Gao, Hongxiang Hu, Simon Zhou - Acta Pharmaceutica Sinica B - Volume 12, Issue 7, July 2022, Pages 3049-3062
JC Discovery® develops highly predictive in vitro and in vivo models of human diseases to increase the clinical translatability.
Based on its combined founder expertise (Center of Immunophenomics - Ciphe and Janvier Labs), JC Discovery® has long-standing expertise in advanced gene editing and immunology, allowing the design of predictive in vitro and in vivo preclinical models that better recapitulate human physiology and accurately evaluate drugs.
JC Discovery® helps leading biopharmaceutical companies and academic research institutions to validate and develop novel therapeutic candidates acting on immune system in the field of immuno-oncology, inflammation, auto-immune, and infectious diseases.
JC Discovery® increases the clinical translatability of your treatment.
At JC Discovery®, we provide streamlined solutions encompassing genetic engineering models and preclinical services to make drug discovery phase a strategic time frame to decide the future of your drug, at the early phase of development.
Long-lasting expertise, state-of-the-art infrastructure and robust data mining, JC Discovery® gives access to key stage services enabling drug target validation, compound validation and clinical trial optimization. Understanding core pathways within the immune system to comprehensively study disease mechanisms are also translational preclinical services that we are offering.
Characterise your models (immunoprofiling) and access knowledge with gold-standard immunomics.
Identify your drug candidate targets using human primary T lymphocytes combined with interatomics technology.
.svg)
Ensure the fast colony expansion and preservation to enter preclinical testing with large and secured cohorts.
.png)
Every therapeutic that plays a direct or indirect role in immune system modulation.
JC Discovery® benefits from the latest advances in genome editing (CRISPR-Cas9 licence) in compliance with the 3R rules (reduce, refine, replace), ethics and animal welfare. We possess the licences allowing you to keep ownership of your proprietary models.
.webp)
We are mapping the immune system at unprecedented granularity to develop and improve the next-generation of immuno-modulating therapeutics.
The use of stringent quality control, data normalization, and data analysis by our experts, enables interpretation of biological phenomena across disease models acting on immune system.
- Define efficacy with well-targeted in vitro and in vivo models
- Decipher the mechanism of action
Based on its combined founder expertise (CIPHE - Center of Immunophenomics and Janvier Labs), JC Discovery® has long-standing expertise in advanced gene editing and immunology allowing design of predictive in vitro and in vivo preclinical models that better recapitulate human physiology and accurately evaluate drugs.
We are a multidisciplinary team of immunologists, engineers, computer scientists, and entrepreneurs focused on functional genomics and an understanding of the immune system in human diseases to empower biomedical community and improve human health.
JC Discovery® has decades of experience in leading successful projects with innovation-driven biopharmaceutical companies and academic institutions to validate and develop novel therapeutic candidates.
Based on its combined founder expertise (CIPHE - Center of Immunophenomics and Janvier Labs), JC DiscoveryTM has long-standing expertise in advanced gene editing and immunology allowing design of predictive in vitro and in vivo preclinical model systems that better recapitulate human physiology and accurately evaluate drugs.
We are a multidisciplinary team of immunologists, engineers, computer scientists, and entrepreneurs focused on functional genomics and an understanding of the immune system in human diseases to empower biomedical community and improve human health.
JC DiscoveryTM has decades experience in leading successful projects with innovation-driven biopharmaceutical companies and academic institutions to validate and develop novel therapeutic candidates acting on immune system.
With the aim to achieve our goals of innovation and quality, we partner with reknowed organizations around the world.
At JC Discovery®, we seek out high quality partners to provide researchers additional novel high-value models and services. With expertise, we share our passion for drug innovation.
JC Discovery® has decades of experience in leading successful projects with innovation-driven biopharmaceutical companies and academic institutions to validate and develop novel therapeutic candidates acting on immune system.
See MorePreclinical studies
Preclinical mouse and rat models
R&D collaborations
From promising to validated immuno-therapeutics JC Discovery offers you a unique & complete pipeline to help you make the right decisions and optimize your drug candidate from early preclinical phases
Preclinical studies
Preclinical mouse and rat models
R&D collaborations
.svg)
.png)
